Quoin Pharmaceuticals, LTD Schedule 13G passive stakes

Several entities affiliated with Millennium Management have reported beneficial ownership of 5.5% of Quoin Pharmaceuticals Ltd.'s ordinary shares.

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 4.9% beneficial ownership stake in Quoin Pharmaceuticals, Ltd.

Stonepine Capital Management has filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Quoin Pharmaceuticals, Ltd.

Woodline Partners LP has disclosed a beneficial ownership of 4.4% of Quoin Pharmaceuticals, Ltd.'s ordinary shares, holding 2,785,370 shares as of March 31, 2026.

Aberdeen Group plc and abrdn Inc. have filed a Schedule 13G, reporting beneficial ownership of 75,000 American Depositary Shares in Quoin Pharmaceuticals, Ltd., representing 4.16% of the class.

Integrated Core Strategies (US) LLC and Millennium Management LLC, along with affiliates, reported reducing their beneficial ownership in Quoin Pharmaceuticals Ltd. to 4.6%.

Ikarian Capital and Neil Shahrestani have reported a 12.6% beneficial ownership stake in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.

Stonepine Capital Management and its affiliates have reported a 10.6% beneficial ownership stake in Quoin Pharmaceuticals, Ltd., primarily through American Depositary Shares and warrants.

Aberdeen Group plc and its subsidiary abrdn Inc. have disclosed a beneficial ownership of 8.94% in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.

Stonepine Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Quoin Pharmaceuticals, Ltd., primarily through American Depositary Shares and warrants.

Ikarian Capital and Neil Shahrestani have reported a significant 25.2% beneficial ownership stake in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.

Resolute Capital Asset Partners and its fund have reported an 8.5% beneficial ownership stake in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.

Millennium Management and affiliated entities have reported a 9.0% beneficial ownership stake in Quoin Pharmaceuticals Ltd. through a Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Quoin Pharmaceuticals, Ltd.'s American Depositary Shares.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% in Quoin Pharmaceuticals, Ltd. as of December 31, 2024.